{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T10:45:57Z","timestamp":1793011557715,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11904-019-00420-1","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T09:25:01Z","timestamp":1547630701000},"page":"76-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders"],"prefix":"10.1007","volume":"16","author":[{"given":"Aylin","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Spudich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"issue":"12","key":"420_CR1","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1523\/JNEUROSCI.10-12-03782.1990","volume":"10","author":"A Represa","year":"1990","unstructured":"Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci. 1990;10(12):3782\u201392.","journal-title":"J Neurosci"},{"issue":"19","key":"420_CR2","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1038\/emboj.2009.236","volume":"28","author":"L Zhong","year":"2009","unstructured":"Zhong L, Cherry T, Bies CE, Florence MA, Gerges NZ. Neurogranin enhances synaptic strength through its interaction with calmodulin. EMBO J. 2009;28(19):3027\u201339.","journal-title":"EMBO J"},{"issue":"4","key":"420_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4161\/cib.3.4.11763","volume":"3","author":"L Zhong","year":"2010","unstructured":"Zhong L, Gerges NZ. Neurogranin and synaptic plasticity balance. Commun Integr Biol. 2010;3(4):340\u20132.","journal-title":"Commun Integr Biol"},{"issue":"21","key":"420_CR4","doi-asserted-by":"publisher","first-page":"11232","DOI":"10.1073\/pnas.210184697","volume":"97","author":"JH Pak","year":"2000","unstructured":"Pak JH, Huang FL, Li J, Balschun D, Reymann KG, Chiang C, et al. Involvement of neurogranin in the modulation of calcium\/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci U S A. 2000;97(21):11232\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"420_CR5","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1212\/WNL.0000000000004569","volume":"89","author":"KB Casaletto","year":"2017","unstructured":"Casaletto KB, Elahi FM, Bettcher BM, Neuhaus J, Bendlin BB, Asthana S, et al. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology. 2017;89(17):1782\u20138.","journal-title":"Neurology"},{"issue":"5","key":"420_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457\u201364.","journal-title":"Ann Neurol"},{"issue":"4","key":"420_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380.","journal-title":"Ann Neurol"},{"issue":"5594","key":"420_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Science. 2002;298(5594):789\u201391.","journal-title":"Science"},{"issue":"2","key":"420_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3233\/JAD-2005-7203","volume":"7","author":"PH Reddy","year":"2005","unstructured":"Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W Jr, et al. Differential loss of synaptic proteins in Alzheimer\u2019s disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005;7(2):103\u201317 discussion 173-180.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"420_CR10","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2015","unstructured":"\u2022 Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(10):1180\u201390. One of the first papers to investigate neurogranin in Alzheimer's disease and that high CSF neurogranin levels can predict progression to dementia.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"420_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","volume":"7","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, et al. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls. Alzheimers Res Ther. 2015;7(1):40.","journal-title":"Alzheimers Res Ther"},{"issue":"Pt 11","key":"420_CR12","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillback T, Tornqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain. 2015;138(Pt 11):3373\u201385.","journal-title":"Brain"},{"issue":"5","key":"420_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and prognostic utility of the synaptic marker Neurogranin in Alzheimer disease. JAMA Neurol. 2016;73(5):561\u201371.","journal-title":"JAMA Neurol"},{"key":"420_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","volume":"136","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, Hoglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136:363\u201376.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"420_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"\u2022 Wellington H, Paterson RW, Portelius E, Tornqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829\u201335. This paper reports that CSF concentrations are increased in Alzheimer's disease, but not in other neurodegenerative disorders or in healthy controls.","journal-title":"Neurology"},{"issue":"2","key":"420_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/jnc.13881","volume":"141","author":"L Novakova","year":"2017","unstructured":"Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmestrom C, et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2017;141(2):296\u2013304.","journal-title":"J Neurochem"},{"issue":"7","key":"420_CR17","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/JCM.30.7.1768-1771.1992","volume":"30","author":"F Chiodi","year":"1992","unstructured":"Chiodi F, Keys B, Albert J, Hagberg L, Lundeberg J, Uhlen M, et al. Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals. J Clin Microbiol. 1992;30(7):1768\u201371.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"420_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/infdis\/jis326","volume":"206","author":"V Valcour","year":"2012","unstructured":"Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206(2):275\u201382.","journal-title":"J Infect Dis"},{"issue":"6","key":"420_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ana.410190602","volume":"19","author":"BA Navia","year":"1986","unstructured":"Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19(6):517\u201324.","journal-title":"Ann Neurol"},{"issue":"6","key":"420_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ana.410190603","volume":"19","author":"BA Navia","year":"1986","unstructured":"Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol. 1986;19(6):525\u201335.","journal-title":"Ann Neurol"},{"issue":"1","key":"420_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrn2040","volume":"8","author":"R Ellis","year":"2007","unstructured":"Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8(1):33\u201344.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"420_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1750-3639.1999.tb00219.x","volume":"9","author":"IP Everall","year":"1999","unstructured":"Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, et al. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol. 1999;9(2):209\u201317.","journal-title":"Brain Pathol"},{"issue":"29","key":"420_CR23","doi-asserted-by":"publisher","first-page":"10550","DOI":"10.1523\/JNEUROSCI.4403-14.2015","volume":"35","author":"L Festa","year":"2015","unstructured":"Festa L, Gutoskey CJ, Graziano A, Waterhouse BD, Meucci O. Induction of interleukin-1beta by human immunodeficiency virus-1 viral proteins leads to increased levels of neuronal ferritin heavy chain, synaptic injury, and deficits in flexible attention. J Neurosci. 2015;35(29):10550\u201361.","journal-title":"J Neurosci"},{"key":"420_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1742-6405-7-15","volume":"7","author":"L Hagberg","year":"2010","unstructured":"Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther. 2010;7:15.","journal-title":"AIDS Res Ther"},{"issue":"6","key":"420_CR25","doi-asserted-by":"publisher","first-page":"e0157160","DOI":"10.1371\/journal.pone.0157160","volume":"11","author":"A Eden","year":"2016","unstructured":"Eden A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D, et al. Increased Intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PLoS One. 2016;11(6):e0157160.","journal-title":"PLoS One"},{"issue":"2","key":"420_CR26","doi-asserted-by":"publisher","first-page":"e88591","DOI":"10.1371\/journal.pone.0088591","volume":"9","author":"J Jessen Krut","year":"2014","unstructured":"Jessen Krut J, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One. 2014;9(2):e88591.","journal-title":"PLoS One"},{"issue":"8","key":"420_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","volume":"17","author":"A Yilmaz","year":"2017","unstructured":"\u2022 Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn. 2017;17(8):761\u201370. This review describes CSF NFL concentrations across spectrum of HIV-infection and it also provides more precise estimates of age-related upper limits of CSF NFL concentration.","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"420_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00401-006-0037-0","volume":"111","author":"IC Anthony","year":"2006","unstructured":"Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol. 2006;111(6):529\u201338.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"420_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/01.aids.0000161770.06158.5c","volume":"19","author":"DA Green","year":"2005","unstructured":"Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS. 2005;19(4):407\u201311.","journal-title":"AIDS"},{"issue":"2","key":"420_CR30","first-page":"98","volume":"10","author":"BB Gelman","year":"2004","unstructured":"Gelman BB, Schuenke K. Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation. J Neuro-Oncol. 2004;10(2):98\u2013108.","journal-title":"J Neuro-Oncol"},{"issue":"9533","key":"420_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368(9533):387\u2013403.","journal-title":"Lancet"},{"key":"420_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-2377-9-63","volume":"9","author":"M Gisslen","year":"2009","unstructured":"Gisslen M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol. 2009;9:63.","journal-title":"BMC Neurol"},{"issue":"5","key":"420_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/21505594.2016.1212155","volume":"8","author":"JJ Krut","year":"2017","unstructured":"Krut JJ, Price RW, Zetterberg H, Fuchs D, Hagberg L, Yilmaz A, et al. No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau). Virulence. 2017;8(5):599\u2013604.","journal-title":"Virulence"},{"issue":"23","key":"420_CR34","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1212\/WNL.0b013e3181c5b445","volume":"73","author":"DB Clifford","year":"2009","unstructured":"Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology. 2009;73(23):1982\u20137.","journal-title":"Neurology"},{"issue":"1","key":"420_CR35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12974-018-1160-2","volume":"15","author":"D Guha","year":"2018","unstructured":"Guha D, Wagner MCE, Ayyavoo V. Human immunodeficiency virus type 1 (HIV-1)-mediated neuroinflammation dysregulates neurogranin and induces synaptodendritic injury. J Neuroinflammation. 2018;15(1):126.","journal-title":"J Neuroinflammation"},{"key":"420_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12981-015-0063-x","volume":"12","author":"S Makitalo","year":"2015","unstructured":"Makitalo S, Mellgren A, Borgh E, Kilander L, Skillback T, Zetterberg H, et al. The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer\u2019s disease. AIDS Res Ther. 2015;12:23.","journal-title":"AIDS Res Ther"},{"issue":"2","key":"420_CR37","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/clinchem\/34.2.466","volume":"34","author":"D Fuchs","year":"1988","unstructured":"Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker in HIV infection. Clin Chem. 1988;34(2):466\u20137.","journal-title":"Clin Chem"},{"issue":"1","key":"420_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neulet.2008.04.046","volume":"438","author":"OD Cano","year":"2008","unstructured":"Cano OD, Neurauter G, Fuchs D, Shearer GM, Boasso A. Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells. Neurosci Lett. 2008;438(1):22\u20135.","journal-title":"Neurosci Lett"},{"issue":"1","key":"420_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1212\/WNL.41.1.69","volume":"41","author":"DE Griffin","year":"1991","unstructured":"Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology. 1991;41(1):69\u201374.","journal-title":"Neurology"},{"issue":"4","key":"420_CR40","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1086\/514001","volume":"175","author":"BJ Brew","year":"1997","unstructured":"Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis. 1997;175(4):963\u20136.","journal-title":"J Infect Dis"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-019-00420-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-019-00420-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-019-00420-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T16:54:32Z","timestamp":1606064072000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-019-00420-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1007\/s11904-019-00420-1","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]},"assertion":[{"value":"16 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Aylin Yilmaz, Dietmar Fuchs, Serena Spudich, and Richard W. Price declare that they have no conflict of interest. Henrik Zetterberg has served at scientific advisory boards for Eli Lilly, Roche Diagnostics and Wave, has received travel support from Teva, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Kaj Blennow has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the regional ethics committees and informed consent was obtained from the participants. No animal experiments were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}